Celgene Corporation (NASDAQ:CELG)‘s stock had its “buy” rating reissued by Royal Bank Of Canada in a research note issued to investors on Thursday. They presently have a $173.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 18.07% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Morgan Stanley cut Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a report on Thursday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Tuesday, September 26th. Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Thursday, September 21st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a report on Friday, September 15th. Finally, Mizuho upped their target price on Celgene Corporation from $134.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twenty-one have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $150.54.

Shares of Celgene Corporation (NASDAQ:CELG) traded down 5.36% during mid-day trading on Thursday, reaching $138.66. The company had a trading volume of 5,865,341 shares. The company has a market cap of $108.48 billion, a price-to-earnings ratio of 42.94 and a beta of 1.88. The firm’s 50-day moving average price is $138.73 and its 200 day moving average price is $129.37. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the prior year, the firm earned $1.44 EPS. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts expect that Celgene Corporation will post $7.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (CELG) Receives Buy Rating from Royal Bank Of Canada” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/05/celgene-corporation-celg-receives-buy-rating-from-royal-bank-of-canada.html.

In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 in the last 90 days. Corporate insiders own 0.95% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Neuberger Berman Group LLC lifted its holdings in shares of Celgene Corporation by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after purchasing an additional 71,729 shares in the last quarter. Lincoln Capital Corp lifted its holdings in shares of Celgene Corporation by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 185 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after purchasing an additional 588,000 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Celgene Corporation by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after purchasing an additional 54,210 shares in the last quarter. Finally, Iguana Healthcare Management LLC lifted its holdings in shares of Celgene Corporation by 12.5% in the first quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 79.36% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.